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ABSTRACT Because several peptides ornally found in the
pituitary as within the central nervous system have been l i
in lymphoid tissues and because somatostatin (soma in-
release-inhibiting hormone, SRIH) can act on cells ofthe immune
system, we searched for this peptide in lymphoid organs. We
demonstrated that SRIH mRNA exists in lymphoid tissue, albeit
in smaller levels than in the perive region of the hypo-
taus, the brain region that contains the highest level of this
mRNA. SRIH mRNA was found in the spleen and thymus ofmale
rats and in the spleen, thymus, and bursa of Fabricius of the
chicken. Its loc ton in the bursa indices that the peptide
must be present in B lymphocytes since this is the site of origin of
B lymphocytes in birds. The SRII concentration in these lym-
phoid organs as determined by radloimmunoassay was greater in
the thymus than in the spleen of the rat. These concentrations
were 50 times less than those found in the periventricular region
of the hypodtalmus, the site ofthe perikarya ofSRIH-containing
neurons. In the chicken, as in the rat, the concentration of SRII
was greater in the thymus than in the spleen; it was present in the
bursa ofFabridus, also in higher concentration than in the spleen.
Fluorescence immucytochemir revealed the presence of
SRIH-positive cells in dusters inside the white pulp and more
dispersed within the red pulp ofthe spleen ofboth the rat and the
chicken. The thymus from these species o contained SRIH-
positive cells within the medulla and around the ctcomedullaryjunction. In the chicken, there were large'dusters of SRIH-
positive cells in the medullary portion ofeach nodule ofthe bursa
ofFabricius. Preabsorptionoftheprimayantiseru orreplacing
this antiserum with normal rabbit serum verified the specificity of
aning. Sequential immunostainingof the same sections from rat
spleen using first SRIH antibody and subsequently a monoclonal
antibody against a rat B-cell surface antigen revealed the presence
ofSRIH immunoreactivity in some, but not all, B cells. Other cell
types in spleen not yet identified also stained positively with the
SR.II antibody but were not reactive to monoclonal antibodies to
rat Thy-1.1, a marker for all the thymic T lymphocytes. The
possibility that SRIH is present in other populations of cells in the
spleen cannot be ruled out. Sequential immu nin of the
same sections of rat thymus revealed the presence of SRIH
immunoreactivity in a small population of T lymphocytes in the
medulla, as revealed by the Thy-1.1 marker. The SRIH-positive
cells were nonimmunoreactivewhen exposed tothe B-cell marker;
however, the possibility thatSRIH is present in other cells was not
investigated. Thus, our results indicate that SRIH is synthesized
and stored in cells of the immune system. SRHI may be secreted
from these cells to exert paracine actions that alter the function
of immune cells in spleen and thymus.
Somatostatin (somatotropin-release-inhibiting hormone,
SRIH), originally described and isolated from the hypothal-
amus (1, 2) by its ability to inhibit growth hormone release
occurs in a variety of endocrine and nonendocrine tissues,
including other parts of the brain, pancreas, stomach, and
duodenum (3, 4). Such a wide distribution of SRIH implies
the hormone has a larger functional significance that extends
beyond the regulation of growth hormone secretion. There is
increasing evidence that SRIH influences numerous bodily
functions including the immune response. Specific receptors
for SRIH have been found on lymphocytes and monocytes (4,
5); it exerts both stimulatory and inhibitory effects on lym-
phocyte proliferation (5-8), inhibits the release of colony-
stimulating factor from activated lymphocytes (9), and sup-
presses immunoglobulin synthesis (5). In contrast to these
inhibitory actions, SRIH enhanced leukocyte-migration-
inhibiting factor formation in activated lymphocytes (5). This
study was conducted to investigate the presence ofSRIH and
its mRNA in the spleen and thymus ofthe rat and chicken and
in the bursa of Fabricius of the chicken, the organ that
exclusively produces B lymphocytes in birds.
MATERIALS AND METHODS
Experimental Animals. Thirty-day-old male Sprague-
Dawley-derived rats (Holtzmann, Madison, WI) and chick-
ens, which were 7-week-old Leghorn poults, were used as
tissue donors. The rats were housed in group cages (10 rats
per cage) under controlled conditions of light (hours lights on
0500-1900) and temperature [24 ± 1PC (mean ± range)]. Rat
Chow and water were provided ad libitum. The chickens
were normal healthy birds from the Texas A & M University
poultry farm. The animals were killed by decapitation, and
the tissue samples were quickly collected, frozen in liquid
nitrogen, and stored at -700C until analyzed.
Plasmid Preparation. A cDNA probe for rat prepro-SRIH
in expression vector pSP65 (10) was generously provided by
R. H. Goodman (University of Oregon School of Medicine,
Portland, OR). Escherichia coli Y1088 were transformed with
this vector using the calcium chloride procedure (11) and the
culture was expanded in LB broth containing ampicillin (50
pug/ml). The plasmid was isolated by the alkaline lysis
method (12) and purified with polyethylene glycol (12). The
presence ofthe SRIH cDNA probe was initially confirmed by
digestion with the restriction enzymes Xba I and BamHI
followed by separation on a 1% agarose gel and staining with
ethidium bromide. An insert of -500 base pairs was detected,
which is consistent with the size of the rat prepro-SRIH
cDNA insert (13).
SRII cRNA Probe Synthesis and Labeling. The transcrip-
tion mixture (10 1Ad) contained 0.25 ,ug of Sal I-digested SP65
cDNA, 7 units of SP6 RNA polymerase, 10'units of human
placenta RNase inhibitor, 40 mM Tris-HCl (pH 7.9), 1 mM
dithiothreitol, 0.5 mM ATP, 0.5 mM GTP, and 0.5 mM UTP;
Abbreviations: SRIH, somatotropin-release-inhibiting hormone;
PVN, periventricular nucleus.
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25 ;uM [a-32P]CTP (800 Ci/mmol; 1 Ci = 37 GBq) was the
substrate in the synthesis of the RNA probe that was used in
quantitation of SRIH mRNA. After incubation at 370C for 1
h, the transcription mixture was digested with 1 unit of
DNase I at 370C for 10 min, extracted with phenolchloroform,
1:1 (vol/vol), and purified by two precipitations with 2 vol of
ethanol per precipitation in the presence of yeast tRNA (0.7
mg/ml). The RNA probe was washed in ice-cold 70%6 ethanol
(pelleted by centrifugation) and dissolved in Tris/EDTA (TE
= 10 mM Tris-HCl, pH 8.0/1 mM EDTA).
Transcript Speciflcity. Control experiments were per-
formed to demonstrate the specificity of the binding of the
probe for these assays. All controls performedi'(.e., S1
nuclease digestion and hybridization with tR14A and with
sense RNA-for tyrosine hydroxylase, kindly provided by
J. C. Porter (University of Texas Southwestern Medical
Center, Dallas)] resulted in the absence of the nuclease-
resistant fragment.
Quantification ofSRIH mRNA. Total mRNA was extracted
using the guanidinium/hot phenol method of Feramisco et al.
(14). Spleen and thymus from rat and chicken and bursa of
Fabricius (<20 mg)' were homogenized in 0.35 ml of extrac-
tion buffer (4.5 M guanidinium thiocyanate/25 mM sodium
citrate, pH 7.0/10 mM EDTA/1% Sarkosyl/1% 2-mercapto-
ethanol) and extracted with 0.85 ml of a mixture ofphenol, 0.1
M sodium acetate (pH 5.2), and chloroform, 35:15:35 (vol/
vol). Total RNA (10 jig) was hybridized with 50,000 cpm of32P-labeled SRIH RNA probe per tube and subjected to anS1
nuclease protection assay (15) as adapted by Kedzierski and
Porter (16). RNA probe protected by duplex formation with
SRIH mRNA was analyzed by polyacrylamide gel (8% gel/8
M urea) electrophoresis, followed by autoradiography and
densitometry.
RIA of SRIH. The quantity of SRIH present in the tissues
was determined by RIA as-described (17) with minor modi-
fications. The highly specific antiserum (R-11C) was gener-
ously provided by Louis- De Palatis (Dow Chemical). The
characterization of this antiserum has been described (18). In
brief, the antiserum did not crossreact at a 100-fold molar
excess with luteinizing-hormone-releasing factor, vasoactive
intestinal peptide, thyrotropin-releasing hormone, a-melano-
cyte-stimulating hormone, cholecystokinin (1-8), substance
P, and ,3-endorphin. R-11C crossreacts fully with synthetic
SRIH (SRIH-14) and 40%o with SRIH-28. All results were
expressed as pg of SRIH released per mg of protein.
Protein Measurement. Protein was measured by the pro-
cedure of Lowry et al. (19) using bovine serum albumin as the
standard.
Morphdolgical Analyses. The immunofluorescence proto-
col used is identical to that described (20, 21). The following
antisera were used: R-11C, as described above, or JH202
(kindly supplied by S. Kentroti, University of Colorado,
Denver, CO). Both antisera yielded similar results and stain-
ing was evident at dilutions from 1:100 to 1:1600. The addition
of500,ug of SRIH-14 and 500 ug of SRIH-28 to 1 mlofa 1:100
dilution of antiserum resulted in a 85-90%o reduction of
immunostaining. Preabsorption of a 1:1000 dilution of anti-
serum eliminated all immunostaining whien compared with
nonpreabsorbed antisera at this same dilution. Additionally,
specificity of immunostaining was further verified by using
normal rabbit serum in place of the primary antisera.
To determine whether SRIH is present in B or T lympho-
cytes, antibodies to rat lymphocyte cell surface antigens were
used. A monoclonal antibody (Thy-1.1) that recognizes the
Thy-i antigen expressed in all the thymic lymphocytes was
purchased from Amgen Biologicals. Another monoclonal
antibody (MARK-I, 1:1000 dilution), which-recognizes the
surface immunoglobulin present in rat B cells, was gener-
ously provided by J. W. Uhr (Department of Microbiology,
University of Texas Southwestern Medical Center).
Some sections were counterstained with hematoxylin/
eosin or alcian blue/periodic acid-Schiff (AB/PAS) for the
histological analysis of red and white splenic pulp or for the
presence of mast cells in the thymic corticomedullary junc-
tion, respectively.
RESULTS
Validation ofthe mRNA Method. To evaluate the efficiency
of the quantification of SRIH mRNA: several amounts of
total cytoplasmic RNA (5, 10, or 20 pg) were hybridized with
the 32P-labeled SRIH RNA probe. The protected RNA 'du-
plex was analyzed by polyacrylamide gel electrophoresis and
quantified by autoradiography and densitometry. The result-
ing RNA concentration/absorbance curve demonstrated a
linear relationship between the amount of RNA added and
the intensity of the reaction (data not shown).
Loization of SRIH mRNA in Hypotalanmus and Organs
of the Immune System. Cytoplasmic RNA was isolated from
young male rats from tissue from the periventricular nucleus
(PVN) region of the hypothalamus and from the spleen and
probed for the presence of specific SRIH mRNA with an
RNA probe for rat SRIH. Fig. 1 demonstrates the presence
of SRIH mRNA in the PVN and to a lesser extent in spleen.
From the autoradiogram in Fig. 2, it is apparent that the PVN
and the spleen hybridize to a species of mRNA that is w600
bases and was similar to that previously reported (22, 23).
Having identified the SRIH mRNA in the spleen, we
examined also the thymus of the rat and the spleen, thymus,
and bursa of Fabricius of the chicken. The latter organ was
selected since it is the exclusive site for formation of B
lymphocytes in birds. The SRIH mRNA levels from rat and
chicken thymus were detectable (Fig. 2) and were higher than
those found in the spleen of either species. In the chicken, the
bursa of Fabricius had even greater levels of SRIH mRNA
than those found in spleen or thymus. The levels of SRIH
mRNA in all of these organs were significantly less than those
found in the PVN of the hypothalamus, which contains the
highest level of mRNA for SRIH observed in any organ.
SRi Co in Organs of the Iune System.
Since SRIH mRNA was present in these organs, it was
anticipated that SRIH could also be detected by RIA. Indeed,
low and approximately equivalent concentrations of SRIH
were found in both rat and chicken, spleen (Table 1); there
were greater levels in the thymus of both species. The bursa
of Fabricius from the chicken had much higher concentra-
tions than those present in the spleen of the chicken and





FIG. 1. Representative autoradiogram of SRIH mRNA in spleen
(S) and PVN. Molecular weight standards (Std, OX174re DNA/Hae
III fragments) and probe (P) are also shown. The arrow indicates a
standard band size of 603 base pairs. Total RNA (10 Sg) was
hybridized and analyzed as above. Values are listed as densitometric
units in -10Sg of total cytoplasmic RNA isolated from the tissues
previously described. They were as follows: PVN, 132; S, 32 and
38.
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FIG. 2. S1 nuclease protection assay of SRIH mRNA in 10 ,ug of
total RNA in spleen (S) and thymus (C) from rat and chicken, and in
bursa of Fabricius (B) of the chicken.
The concentrations of SRIH in all these organs were signif-
icantly less than those found in PVN (1362 + 18 pg of SRIH
per mg of protein).
Loclization of SRIH in Lymphoid Organs by Imnunocy-
tochemistry. Immunocytochemical staining of 10-jum frozen
sections mounted on coverslips revealed that SRIH-positive
cells were present in large clumps within both rat (Fig. 3A)
and chicken (data not shown) spleen. Some sections were
counterstained with hematoxylin/eosin and examination of
these sections verified that some of these clumps of SRIH
cells were clearly within the splenic white pulp. Other
positive cells, which were outside these clumps and were
more dispersed (Fig. 3C), were localized to the red pulp.
In some experiments, after immunofluorescence and pho-
tography of the SRIH-positive cells in the rat, tissues were
washed in phosphate buffer then subjected to a counterstain
using specific monoclonal antibodies to either B or T lym-
phocytes. This reaction employed the Vectastain ABC pro-
cedure utilizing diaminobenzadine as the chromogen. Fig. 3
B and D shows the same fields as shown in Fig. 3 A and C,
respectively. As can be seen with this low magnification, the
large clump of SRIH-positive cells (Fig. 3A) in spleen were
found to be predominantly B lymphocytes as revealed by
using the antiserum (MARK-I) to the B-cell surface antigen
(Fig. 3B). Importantly, all B lymphocytes were not positive
for SRIH and, conversely, some SRIH-positive cells may be
yet another cell type. This becomes more apparent by
examining the more dispersed cells depicted in Fig. 3 C and
D. Additionally, counterstaining SRIH-positive cells in
spleen using antiserum to the surface antigen Thy-1.1 re-
vealed no positive immunostaining in rat T cells (data not
shown). These results do not rule out the possibility that
other cells may contain SRIH within the spleen.
Similarly, the thymus from both species exhibited intense
SRIH-positive cells in small clusters within the medulla, with
less intensely stained cells around the corticomedullaryjunc-
tion. Fig. 4 depicts a representative section ofthe rat thymus.
Some sections of the rat thymus were then counterstained
with the MARK-I, B-cell surface marker as described above,
and results indicate that the SRIH-positive cells were not B
lymphocytes. Other sections were counterstained with anti-
Thy-1.1, the T-cell marker, and those results demonstrate the
presence of SRIH immunoreactivity in a small population of
T lymphocytes at the corticomedullary junction (Fig. 5).
Table 1. Concentrations of SRIH in the immune system organs
Species Tissue n SRIH, pg/mg of protein
Rat Spleen 4 34.44 ± 6.6
Thymus 5 78.10 + 7.9*
Chicken Spleen 4 42.4 ± 4.7
Thymus 3 197.8 ± 28.5t
Bursa of Fabricius 3 129.6 ± 2.5t
Data are mean ± SEM. *, P < 0.005 vs. rat spleen; t, P < 0.001
vs. chicken spleen.
FIG. 3. Presence of SRIH-immunoreactive B lymphocytes in the
rat spleen. (A) Distinct clumps of splenic cells (arrows) positive for
SRIH by immunofluorescent staining. v, Vessel. (x70.) (B) Same
field depicted in A demonstrating that the clumps of SRIH-positive
cells are also shown to stain positive with monoclonal antibodies to
a rat B-lymphocyte surface antigen. (x70.) (C) Several dispersed
SRIH-positive (single arrows) cells in the red pulp. (x 175.) (D) Same
field depicted in C demonstrating that the same SRIH-positive cells
are B lymphocytes (arrows). (x175.) By comparing C and D, it can
also be seen that some ofthe B cells shown inD (arrowheads) are not
SRIH-positive (see C), and likewise, some SRIH cells shown in C
(double arrows) are not B lymphocytes (see D).
Again, these results do not rule out the possibility that other
cells in the thymus, possibly macrophages, may contain
SRIH. In a separate experiment the possibility that the
positive SRIH cells at the corticomedullary junction were
FIG. 4. Immunoreactive SRIH cells in the rat thymus. Note that
the majority of immunostaining was present in the medullary (ar-
rows) portion of this thymic lobule. c, Cortex. (x175.)
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FIG. 5. Presence of SRIH-positive T lymphocytes in the rat
thymus. (A) A few SRIH-positive cells (arrows) at the corticomed-
ullary junction. (B) Same field depicted inA demonstrating that some
of these SRIH-positive cells are T lymphocytes (arrows), as revealed
by a monoclonal antibody to Thy-1.1. These photos also show that
the majority of T lymphocytes (arrowheads) are not SRIH-positive
and that some SRIH cells (double arrows) are not T cells. v, Vessel.
(x 135.)
mast cells was ruled out by the alcian blue/periodic acid-
Schiff counterstain procedure.
The chicken bursa of Fabricius also contained SRIH-
positive cells. In this organ, the immunoreactive cells were
largely confined to the medullary portion of each nodule (Fig.
6).
DISCUSSION
In the present study we have characterized the presence of
SRIH-specific mRNA in spleen, thymus, and bursa of Fab-
ricius by an S1 nuclease protection assay using a SRIH
complementary RNA probe. These tissues contained only
one species of SRIH mRNA. The length of the message in
these tissues is of a similar size to that seen in the hypothal-
amus (22) and PC-12 cells (23). The SRIH concentrations in
these tissues analyzed by RIA showed a similar pattern as
that seen with SRIH mRNA. These findings were corrobo-
rated by our immunocytochemical studies showing SRIH-
positive cells in thymus, spleen, and bursa of Fabricius.
Finally, double staining revealed that some but not all B
lymphocytes in rat spleen contained SRIH and that this
peptide was also contained in other splenic cells that have not
been identified. Additionally, SRIH was not observed in a
population ofT lymphocytes that express the Thy-1.1 surface
antigen. In the thymus, SRIH was not contained in B
lymphocytes but was found instead to be present in T
lymphocytes. The failure to observe SRIH in some B and T
cells does not mean that these cells do not contain the
FIG. 6. SRIH-positive cells in a representative nodule of the
bursa of Fabricius of the chicken. Note the more intense immuno-
reactivity in the medullary portion of this nodule. (x 138.)
peptide. It could be that the SRIH is only present in some
specific subpopulations of B and T lymphocytes and/or that
the quantity is below the sensitivity of the immunocytochem-
ical method employed.
The fact that SRIH is contained in B lymphocytes was
confirmed by its localization by immunocytochemistry to
cells of the bursa of Fabricius, which is the exclusive organ
forming B lymphocytes in the bird. Here it was detected in
the medulla of the nodules of the bursa, which is the site of
localization of the immature B cells. This suggests that SRIH
is present in greater abundance in immature rather than adult
B cells.
Our results provide strong evidence that SRIH is synthe-
sized in and is present in lymphocytes in the organs of the
immune system. These observations strongly suggest that
SRIH may play a role in regulating the activity of these cells.
It is probably released from these cells to exert paracrine
actions on adjacent immune cells in lymphoid organs. Indeed,
a number of such actions have been characterized. SRIH can
either inhibit or stimulate lymphocyte proliferation (5-8),
inhibit the release of colony-stimulating factor from activated
lymphocytes (9), and suppress immunoglobulin synthesis (5),
whereas it enhances leukocyte migration-inhibiting factor
formation in activated lymphocytes (7). These actions are
probably mediated by combination of SRIH with its specific
receptors, which have been localized on the surface of
lymphocytes and monocytes (4, 5).
The evidence is mounting that many peptides produced in
the brain and gastrointestinal tract are contained within
immune cells. Examples include adrenocorticotropin hor-
mone (24), f3-endorphin (25), vasoactive intestinal polypep-
tide (26, 27), thyrotropin (28), chorionic gonadotropin (29),
follicle-stimulating hormone (30), luteinizing hormone (30),
growth hormone (31), and finally growth-hormone-releasing
hormone (32). In this latter connection, it is tempting to
speculate that growth-hormone-releasing hormone and SRIH
might have antagonistic paracrine actions on immune cells
just as they affect the release of growth hormone from the
pituitary gland in an opposing manner. Thus, the immune
system and the neuroendocrine system can produce neu-
ropeptides, as well as interleukins and other cytokines, and
also shares receptors for these neuroendocrine and immune
mediators.
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